12670 High Bluff Drive
    San Diego, California 92130
    Tel: +1.858.523.5400 Fax: +1.858.523.5450
    Austin    Moscow
    Beijing    Munich
    Boston    New York
    Brussels    Orange County
    Century City    Paris
April 6, 2022     Chicago    Riyadh
    Dubai    San Diego
VIA EDGAR     Düsseldorf    San Francisco
    Frankfurt    Seoul
    Hamburg    Shanghai
    Hong Kong    Silicon Valley
Ms. Jane Park     Houston    Singapore
Office of Life Sciences     London    Tel Aviv
Division of Corporation Finance     Los Angeles    Tokyo
U.S. Securities and Exchange Commission     Madrid    Washington, D.C.
100 F Street N.E.     Milan   
Washington, D.C. 20549       



HilleVax, Inc.

Amendment No. 2 to Draft Registration Statement on Form S-1

Submitted February 28, 2022

CIK No. 0001888012

Dear Ms. Park:

We are in receipt of the Staff’s letter dated March 3, 2022 with respect to the above-referenced confidential draft amended Registration Statement (the “Amended Draft Registration Statement”). We are responding to the Staff’s comments on behalf of HilleVax, Inc. (“HilleVax” or the “Company”) as set forth below. Simultaneously with the submission of this letter, the Company is publicly filing via EDGAR the Registration Statement on Form S-1 (the “Registration Statement”) responding to the Staff’s comments and updating the Amended Draft Registration Statement.

The Company’s responses set forth in this letter are numbered to correspond to the numbered comments in the Staff’s letter. All terms used but not defined herein have the meanings assigned to such terms in the Registration Statement. For ease of reference, we have set forth the Staff’s comments and the Company’s response for each item below.

Amendment No. 2 to Draft Registration Statement submitted on February 28, 2022

Our amended and restated certificate of incorporation and amended and restated bylaws, page 75



We note your disclosure on page 75 that the exclusive forum in your amended and restated certificate of incorporation does not apply to suits brought to enforce a duty or liability created by the Exchange Act. Please ensure that the exclusive forum provision in your amended and restated certificate of incorporation states this clearly.

April 6, 2022

Page 2



HilleVax’s Response: The Company respectfully advises the Staff that the amended and restated certificate of incorporation filed as Exhibit 3.3 to the Registration Statement clearly states the foregoing Exchange Act provision.

Efficacy trials in adults, page 118



Please revise to disclose the number of participants enrolled in the Challenge trial for your LV01-103 product candidate.

HilleVax’s Response: The Company has revised the disclosure on page 118 of the Registration Statement in response to the Staff’s comment.


Any comments or questions regarding the foregoing should be directed to the undersigned at (858) 523-3962. Thank you in advance for your cooperation in connection with this matter.


Very truly yours,
/s/ Matthew T. Bush

Matthew T. Bush




Tim Buchmiller, Securities and Exchange Commission

Julie Sherman, Securities and Exchange Commission

Terence O’Brien, Securities and Exchange Commission

Robert Hershberg, M.D., Ph.D., HilleVax, Inc.

Wesley C. Holmes, Latham & Watkins LLP

Cheston J. Larson, Latham & Watkins LLP

Alan F. Denenberg, Davis Polk & Wardwell LLP

Emily Roberts, Davis Polk & Wardwell LLP